Aleafia Becomes First Cannabis Stock to Top TSX Venture 50 Performance Rankings
February 25th, 2019
Exclusive, News, Top News
The TSX Venture exchange has become a popular place for cannabis companies to list their shares, particularly after Canada legalized recreational cannabis last year, but 2019 was the first year that a cannabis company topped its annual performance rankings.
Aleafia Health Inc. (TSX-V: ALEF) (OTCQX: ALEAF) (FRA: ARAH), a vertically-integrated licensed producer with a clinic network and over 50,000 patients, was named as the 2019 TSX Venture 50 top performing company of the year. The TMX Group’s annual performance awards are based on three equally weight criteria, including market capitalization growth, share price appreciation and trading volume.
The award demonstrates the company’s increasing popularity in the space. Over the past 52 weeks, the company’s stock price rose from a low of $0.47 to a high of $4.70 before settling at its current levels of around $2.37, making it a popular stock for active traders interested in the cannabis industry. As such, daily trading volume averaged roughly 1.42 million shares over the past three months, providing significant liquidity for investors.
Research Proves a Strong Catalyst
Aleafia Health’s stock reached all-time highs back in late-September when it partnered with Cronos Group Inc. (NASDAQ: CRON) to study the effects of medical cannabis on insomnia and daytime sleepiness. Under the terms of the deal, Cronos Group would provide funding for the study, which would be conducted by doctors at Aleafia’s health clinics. The company also formally launched Aleafia Labs to focus on these research projects.
The company’s stock also moved sharply higher when it announced positive results from its benzodiazepine study. After conducting a study with 146 patients, the company reported that 45.2 percent of patients stopped consuming benzodiazepines—as a sedative or anti-anxiety medication—following a medical cannabis prescription. The patients further reported decreased daily distress due to their medical condition.
These research projects leverage the company’s wholly-owned network of more than 20 Canabo Medical Clinics with over 50,000 patients. With the largest medical cannabis dataset in the world, the company enables researchers to validate cannabis science, product teams to innovate, and management to build a strong portfolio of intellectual property. The division had already generated $612,000 in revenue by the third quarter of 2018.
Appealing to Both Traders & Investors
Many cannabis stocks appeal to active traders that look for important catalysts and price movements, but only a fraction of these companies are also attractive on a fundamental basis to long-term investors. Aleafia Health is an existing licensed producer with an experienced management team, 98,000 kilograms per year of production capacity expected this year, and a network of medical cannabis clinics with over 50,000 patients.
The company already generates tangible revenue from its medical cannabis clinics, research activities and supply agreement with CannTrust Holdings Inc. (TSX: TRST). After merging with Emblem Corp., the company has amassed a significant production footprint that it’s expanding further through strategic investments around the world. At the same time, its massive cannabis dataset provides an invaluable competitive advantage.
Currently, the company trades with a market capitalization of about $375 million, which is lower than many other licensed producers. As the company scales up production and research activity, investors may become increasingly interested in the growing revenue and cash flow. The R&D activity could also pave the way towards valuable revenue streams from licensing, which may help boost revenue and margins over the long-term.
Aleafia Health Inc. (TSX-V: ALEF) (OTCQX: ALEAF) (FRA: ARAH) represents a compelling opportunity within the nascent cannabis industry. In addition to having a very active stock, the company’s business has been rapidly expanding from both a production and research standpoint. Investors may want to keep an eye on the stock as it continues to focus on growing its operations and announcing new research.
For more information, visit the company’s website at www.aleafiahealth.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.